Raubitschek A - Search Results

1

The emerging biology of modern radiation oncology.

Goffman TE, Raubitschek A, Mitchell JB, Glatstein E. Goffman TE, et al. Among authors: raubitschek a. Cancer Res. 1990 Dec 15;50(24):7735-44. Cancer Res. 1990. PMID: 2253216 Review. No abstract available.

2

An isocentric chair for the simulation and treatment of radiation therapy patients.

Miller RW, Raubitschek AA, Harrington FS, van de Geijn J, Ovadia J, Glatstein E. Miller RW, et al. Among authors: raubitschek aa. Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):469-73. doi: 10.1016/0360-3016(91)90798-9. Int J Radiat Oncol Biol Phys. 1991. PMID: 2061123

3

The never-ending controversies in Hodgkin's disease.

Raubitschek A, Glatstein E. Raubitschek A, et al. Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):1115-7. doi: 10.1016/0360-3016(89)90166-1. Int J Radiat Oncol Biol Phys. 1989. PMID: 2808047 No abstract available.

4

Survivors of Hodgkin's disease: prevention of sequelae.

Goffman TE, Raubitschek A, Glatstein E. Goffman TE, et al. Among authors: raubitschek a. South Med J. 1991 Sep;84(9):1108-10. doi: 10.1097/00007611-199109000-00012. South Med J. 1991. PMID: 1909813

5

A staging of lymphomas: practical thoughts on impractical practices.

Raubitschek A, Goffman T, Glatstein E. Raubitschek A, et al. J Natl Cancer Inst Monogr. 1990;(10):13-7. J Natl Cancer Inst Monogr. 1990. PMID: 2346707

6

Dosimetric considerations in treating mediastinal disease with mantle fields: characterization of the dose under mantle blocks.

Miller RW, van de Geijn J, Raubitschek AA, Orr K, Okunieff P, Glatstein E. Miller RW, et al. Among authors: raubitschek aa. Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):1083-95. doi: 10.1016/0360-3016(95)00013-o. Int J Radiat Oncol Biol Phys. 1995. PMID: 7607929

7

Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial.

Longo DL, Glatstein E, Duffey PL, Young RC, Hubbard SM, Urba WJ, Wesley MN, Raubitschek A, Jaffe ES, Wiernik PH, et al. Longo DL, et al. Among authors: raubitschek a. J Clin Oncol. 1991 Jun;9(6):906-17. doi: 10.1200/JCO.1991.9.6.906. J Clin Oncol. 1991. PMID: 2033427 Clinical Trial.

8

Comparison of bone marrow dosimetry and toxic effect of high dose 131I-labeled monoclonal antibodies administered to man.

Larson SM, Raubitschek A, Reynolds JC, Neumann RD, Hellstrom KE, Hellstrom I, Colcher D, Schlom J, Glatstein E, Carrasquillo JA. Larson SM, et al. Among authors: raubitschek a. Int J Rad Appl Instrum B. 1989;16(2):153-8. doi: 10.1016/0883-2897(89)90188-8. Int J Rad Appl Instrum B. 1989. PMID: 2715010

9

Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity.

Kozak RW, Raubitschek A, Mirzadeh S, Brechbiel MW, Junghans RP, Gansow OA, Waldmann TA. Kozak RW, et al. Among authors: raubitschek a. Cancer Res. 1989 May 15;49(10):2639-44. Cancer Res. 1989. PMID: 2785435

10

Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.

Colcher D, Milenic D, Roselli M, Raubitschek A, Yarranton G, King D, Adair J, Whittle N, Bodmer M, Schlom J. Colcher D, et al. Among authors: raubitschek a. Cancer Res. 1989 Apr 1;49(7):1738-45. Cancer Res. 1989. PMID: 2924317

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

135 results

Search Page

Filters